WuXi Biologics Launches EffiX Platform to Enhance Microbial Biologics Manufacturing

• WuXi Biologics has launched EffiX, an E. coli expression system designed to improve yield and stability in recombinant protein and plasmid DNA production.

• The platform supports scalable and cost-effective microbial biologics manufacturing, achieving titers exceeding 15 g/L for non-mAb proteins and over 1 g/L for plasmid DNA.

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has introduced EffiX, a proprietary E. coli expression system engineered to enhance the production of recombinant proteins and plasmid DNA. The platform is designed to deliver high yields, exceptional stability, and scalability in microbial-derived biologics manufacturing.

The demand for microbial-derived biomolecules, including antibody fragments, nanobodies, enzymes, cytokines, and plasmid DNA, is increasing as next-generation therapies continue to evolve. EffiX addresses production challenges in this space, achieving titers exceeding 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA, while maintaining consistent quality and efficiency.

EffiX integrates streamlined processes tailored for projects ranging from early research to commercial manufacturing. By offering a comprehensive Chemistry, Manufacturing, and Controls (CMC) strategy, the platform accelerates biotherapeutic development and provides cost-effective solutions for global partners.

Dr. Chris Chen, CEO of WuXi Biologics, stated, “We are excited to upgrade our microbial solutions with the innovative EffiX platform, which offers our clients exceptional productivity and product quality, along with scalability and flexibility at every stage of development.”